↓ Skip to main content

Pharmacology of the WNT Signaling System

Overview of attention for book
Pharmacology of the WNT Signaling System
Springer International Publishing
Attention for Chapter: WNT Signalling in Osteoarthritis and Its Pharmacological Targeting.
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user

Readers on

mendeley
8 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
WNT Signalling in Osteoarthritis and Its Pharmacological Targeting.
Book title
Pharmacology of the WNT Signaling System
Published in
Handbook of experimental pharmacology, September 2021
DOI 10.1007/164_2021_525
Pubmed ID
Book ISBNs
978-3-03-085498-0, 978-3-03-085499-7
Authors

De Palma, Anna, Nalesso, Giovanna, Palma, Anna De

Abstract

Osteoarthritis (OA) is a highly disabling musculoskeletal condition affecting millions of people worldwide. OA is characterised by progressive destruction and irreversible morphological changes of joint tissues and architecture. At molecular level, de-regulation of several pathways contributes to the disruption of tissue homeostasis in the joint. Overactivation of the WNT/β-catenin signalling pathway has been associated with degenerative processes in OA. However, the multiple layers of complexity in the modulation of the signalling and the still insufficient knowledge of the specific molecular drivers of pathogenetic mechanisms have made difficult the pharmacological targeting of this pathway for therapeutic purposes. This review aims to provide an overview of the WNT/β-catenin signalling in OA with a particular focus on its role in the articular cartilage. Pathway components whose targeting showed therapeutic potential will be highlighted and described. A specific section will be dedicated to Lorecivivint, the first inhibitor of the β-catenin-dependent pathway currently in phase III clinical trial as OA-modifying agent.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 8 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 8 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 2 25%
Researcher 1 13%
Lecturer 1 13%
Unknown 4 50%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 25%
Immunology and Microbiology 1 13%
Medicine and Dentistry 1 13%
Engineering 1 13%
Unknown 3 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2021.
All research outputs
#15,686,478
of 23,310,485 outputs
Outputs from Handbook of experimental pharmacology
#402
of 650 outputs
Outputs of similar age
#248,320
of 430,009 outputs
Outputs of similar age from Handbook of experimental pharmacology
#9
of 21 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 650 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 430,009 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 33rd percentile – i.e., 33% of its contemporaries scored the same or lower than it.